We are live on ! Find out more
RG

Redmile Group Portfolio holdings

AUM $1.51B
1-Year Est. Return 164.17%
This Fund
S&P 500
This Quarter Est. Return
+11.52%
1 Year Est. Return
+164.17%
3 Year Est. Return
+929.47%
5 Year Est. Return
+823.75%
10 Year Est. Return
+18,826.17%
AUM
$1.05B
AUM Growth
+$69.9M
Cap. Flow
+$13.5M
Cap. Flow %
1.29%
Top 10 Hldgs %
49.49%
Holding
62
New
15
Increased
22
Reduced
15
Closed
8

Top Buys

Rank Stock Value
1
ALXN
Alexion Pharmaceuticals
ALXN
+$28.7M
2
MOH icon
Molina Healthcare
MOH
+$27.6M
3
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$26.9M
4
PRTA icon
Prothena Corp
PRTA
+$21.2M
5
NVRO
NEVRO CORP.
NVRO
+$18.2M

Top Sells

Rank Stock Value
1
MDVN
MEDIVATION, INC.
MDVN
+$48.6M
2
IRWD icon
Ironwood Pharmaceuticals
IRWD
+$45.2M
3
SAGE
Sage Therapeutics
SAGE
+$33.8M
4
AGN
Allergan plc
AGN
+$30.7M
5
PEN icon
Penumbra
PEN
+$21.8M

Sector Composition

Rank Sector Weight
1 Healthcare 73.5%
2 Financials 2.71%
3 Communication Services 2.42%
4 Industrials 0.75%
5 Consumer Staples 0.61%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SYRS
26
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$15.1M 1.44%
+94,618
New +$17.2M
NDRM
27
DELISTED
NeuroDerm Ltd. Ordinary Shares
NDRM
$13.3M 1.28%
821,445
-359,442
-30% -$6.05M
CMRX
28
DELISTED
Chimerix, Inc.
CMRX
$12.9M 1.23%
+3,288,376
New +$16.2M
OXFD
29
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
$12.9M 1.23%
1,428,094
+552,006
+63% +$5.41M
CRL icon
30
Charles River Laboratories
CRL
$10.5B
$10.8M 1.04%
131,606
+21,800
+20% +$1.8M
ADPT
31
DELISTED
Adeptus Health Inc
ADPT
$8.45M 0.81%
+163,474
New +$9.8M
PGND
32
DELISTED
PRESS GANEY HOLDINGS INC COM STK (DE)
PGND
$7.8M 0.75%
198,214
-20,000
-9% -$669K
SPNC
33
DELISTED
Spectranetics Corp
SPNC
$7.52M 0.72%
+401,836
New +$7.08M
CTMX icon
34
CytomX Therapeutics
CTMX
$725M
$7.5M 0.72%
733,899
+4,200
+0.6% +$47.9K
CFMS
35
DELISTED
Conformis, Inc. Common Stock
CFMS
$7.36M 0.7%
41,913
+10,219
+32% +$2.4M
EVHC
36
DELISTED
Envision Healthcare Holdings Inc
EVHC
$7.33M 0.7%
+96,499
New +$6.86M
PMC
37
DELISTED
PharMerica Corporation
PMC
$6.51M 0.62%
+263,862
New +$6.55M
WOOF
38
DELISTED
VCA Inc.
WOOF
$6.37M 0.61%
94,200
-113,600
-55% -$7.21M
EHTH icon
39
eHealth
EHTH
$44.8M
$5.98M 0.57%
426,242
+4,500
+1% +$54.6K
IRWD icon
40
Ironwood Pharmaceuticals
IRWD
$639M
$5.79M 0.55%
528,597
-4,629,712
-90% -$45.2M
ARA
41
DELISTED
American Renal Associates Holdings, Inc
ARA
$4.34M 0.41%
+149,900
New +$4.17M
NVTA
42
DELISTED
Invitae Corporation
NVTA
$4.03M 0.38%
544,939
-115,190
-17% -$1.07M
PRQR icon
43
ProQR Therapeutics
PRQR
$255M
$2.81M 0.27%
581,638
+28,925
+5% +$149K
FATE icon
44
Fate Therapeutics
FATE
$301M
$2.55M 0.24%
1,502,180
+15,200
+1% +$27.6K
SNDX icon
45
Syndax Pharmaceuticals
SNDX
$1.95B
$2.47M 0.24%
250,830
-12,170
-5% -$167K
BPMC
46
DELISTED
Blueprint Medicines
BPMC
$574K 0.05%
28,353
+1,298
+5% +$23.6K
SIOX
47
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
$321K 0.03%
3,125
+1,875
+150% +$187K
BIIB icon
48
Biogen
BIIB
$29.2B
$297K 0.03%
+1,229
New +$324K
LHCG
49
DELISTED
LHC Group LLC
LHCG
$216K 0.02%
+5,000
New +$204K
TMH
50
DELISTED
Team Health Holdings Inc
TMH
$203K 0.02%
+5,000
New +$218K
1
2
3

Similar funds

KP
Keel Point Huntsville, Alabama $1.51B AUM 20.06% 1-Year Est. Return
FMI
F/M Investments Washington, District of Columbia $1.51B AUM 25.86% 1-Year Est. Return
FCM
Fairholme Capital Management South Miami, Florida $1.51B AUM 28.27% 1-Year Est. Return
SCM
SG Capital Management Chicago, Illinois $1.51B AUM 49.98% 1-Year Est. Return
PP
PDS Planning Dublin, Ohio $1.52B AUM 18.08% 1-Year Est. Return
AM
Ares Management Los Angeles, California $1.52B AUM 12.97% 1-Year Est. Return
BFO
Boston Family Office Boston, Massachusetts $1.5B AUM 11.68% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return

Redmile Group's Q2 2016 Portfolio in Review

As of Q2 2016, Redmile Group held 62 positions worth $1.05B, up 7.1% from $977M the previous quarter. Its ten largest holdings account for 49% of the portfolio.

Redmile Group's Q2 2016 filing shows 15 new, 22 increased, 15 reduced and 8 closed positions. Its largest new stake was Alexion Pharmaceuticals: 202,400 shares worth $23.6M. The largest sale was MEDIVATION, INC., an estimated $48.6M.

By sector, the portfolio is most concentrated in Healthcare at 73% of assets, down from 77% a quarter earlier, followed by Financials and Communication Services.

  • Redmile Group's largest Q2 2016 buy was Alexion Pharmaceuticals: 202,400 shares worth $23.6M.
  • Redmile Group added most to Molina Healthcare in Q2 2016, an estimated $27.6M increase.
  • Redmile Group's biggest Q2 2016 reduction was MEDIVATION, INC., cutting an estimated $48.6M.
  • Redmile Group fully exited Sage Therapeutics in Q2 2016, selling an estimated $33.8M.
  • Redmile Group's ten largest holdings make up 49% of its $1.05B portfolio in Q2 2016.
  • Redmile Group opened 15 new positions and closed 8 in Q2 2016.
  • Redmile Group's portfolio value rose 7.1% quarter-over-quarter to $1.05B.

Based on Redmile Group's 13F filing for Q2 2016, filed 16 Aug 2016.